Ionis Pharmaceuticals, Inc. reported favorable primary results from the HALOS Phase 1/2a open-label trial of ION582 for Angelman syndrome.

Ionis Pharmaceuticals, Inc. and Biogen Inc. have decided to discontinue the development of BIIB105 (ION541) following the initial outcomes from the Phase 1/2 ALSpire trial.

Carisma Therapeutics reports initial patient dosed in Phase 1 study of CT-0525, an innovative HER2-focused CAR-monocyte therapy.

The FDA has greenlit Imdelltra™ (tarlatamab-dlle), marking the first T-cell engager therapy for extensive-stage small cell lung cancer.

Proteologix’s lineup includes PX128, a bispecific antibody that targets both IL-13 plus TSLP. PX128 is poised to advance into phase 1 development for the treatment of moderate to severe atopic dermatitis and asthma.

Bayer Begins Phase I Trial of 225Ac-PSMA-Trillium Targeted Radionuclide Therapy for Advanced Metastatic Prostate Cancer.

The U.S. FDA has approved Bristol Myers Squibb's CAR T cell therapy Breyanzi for treating relapsed or refractory follicular lymphoma.

Genentech Announces Favorable Phase Ib Outcomes for Dual GLP-1/GIP Receptor Agonist CT-388 in Obesity Patients.

A2 Biotherapeutics has reported the administration of the initial dose to the first participant in the Phase 1 clinical trial of A2B694.

Elinzanetant greatly decreases the occurrence and intensity of moderate to severe hot flashes tied to menopause.

Pheast Therapeutics revealed the initial showcasing of preclinical data for PHST001, an anti-CD24 antibody drug candidate.

Azitra, Inc. Reveals Encouraging Preclinical Data on ATR-12 and Clinical Plan for Netherton Syndrome at ASGCT Annual Conference.